Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06723535 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT06723535 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 27 participants.
The verdict
NCT06723535, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278. This study plans to use a staged design based on RI severity.
Interventions
- DRUG BMS-986278
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-12-07 |
| Est. Completion | 2025-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06723535
The ClinicalTrials.gov registry entry for NCT06723535 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986278 is the first listed.
NCT06723535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06723535 about?
NCT06723535 is a clinical study titled "A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis". The purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278. This study plans to use a staged design based on RI severity.
What is the current status of trial NCT06723535?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2024-12-07. Estimated completion is 2025-09-19.
What interventions are being tested in trial NCT06723535?
The interventions under investigation include: BMS-986278 (DRUG).
Who is sponsoring clinical trial NCT06723535?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.